Pharma Focus Europe
ThermoFisher Scientific - Custom and Bulks

Almac Group's Groundbreaking £80 Million Expansion Investment in Northern Ireland

Introduction:

The Almac Group has unveiled an £80 million investment program to construct new manufacturing, production, and diagnostic laboratory facilities at its Global Headquarters in Craigavon, Northern Ireland.

Features:

This investment will result in the creation of over 550 jobs locally, covering a wide range of roles in both lab and non-lab areas. Recruitment is already underway for some of these positions, and the company aims to generate a total of 1,000 jobs in Northern Ireland over the next three years through its international hiring campaign.

Almac Pharma Services is involved in the development and commercialization of treatment options across various therapeutic areas, including oncology and immunology. Almac Diagnostic Services offers solutions for biomarker discovery, development, and commercialization to biopharmaceutical partners worldwide.

The first major project entails the construction of a 100,000 square-foot state-of-the-art multi-product Good Manufacturing Practice (GMP) facility for Almac Pharma Services. This facility, operational from Q3 2024, will expand manufacturing capabilities, particularly for solid oral dose products.

The facility is designed with flexibility in mind, allowing clients to install technology specific to their needs, and it provides additional capacity for strategic production contracts.

The second significant project involves a 40,000 square-foot, four-story diagnostic development and manufacturing center for Almac Diagnostic Services, expected to be completed by Q1 2024.

This facility will enable Almac Diagnostic Services to expand assay development capabilities and manufacture and distribute Companion Diagnostic (CDx) kits at a commercial scale to meet growing client demand.

This expansion enhances Almac's early-phase biomarker development capabilities through to assay development and deployment in clinical trials, solidifying its position as a partner of choice for manufacturing and commercialization of companion diagnostics for pharmaceutical companies.

Specifications:

Name: Almac Group

Type: Expansion

Year: 2024

magazine-slider-img
Get instant
access to our latest e-book
Pall+CytivaAdvertisement
patheon - Mastering API production at every scaleLab Indonesia 20247th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing PharmaWorld Vaccine Congress Europe 2024